Essential components of a report on a newly diagnosed MDS (or diagnosis of MDS before enrollment in a clinical trial)
| Classification subtype according to WHO revised fourth edition, WHO fifth edition, and ICC schemes |
| Qualifying terms if the case is therapy-related/postcytotoxic therapy and/or in the background of a germ line predisposition condition |
| CBC and WBC differential from the date of the bone marrow sample, including peripheral blood blast percentage |
| Bone marrow blast percentage on bone marrow aspirate smear∗ |
| Presence of any significant (≥10%) dysplasia in each hematopoietic lineage (granulocytic, erythroid, and megakaryocytic) and any Auer rods |
| Presence or absence of ring sideroblasts on iron stain and their percentage of mature erythroid cells in the marrow |
| Bone marrow cellularity assessment (percentage) |
| Bone marrow fibrosis grade (MF 0-3) |
| Presence of any concomitant pathologies, such as metastasis, infection, lymphoma, mast cell disease, or multiple myeloma |
| Bone marrow karyotype (ISCN nomenclature) and any FISH results |
| Any pathogenic mutations identified on NGS panel, including VAF of each mutation |
| Classification subtype according to WHO revised fourth edition, WHO fifth edition, and ICC schemes |
| Qualifying terms if the case is therapy-related/postcytotoxic therapy and/or in the background of a germ line predisposition condition |
| CBC and WBC differential from the date of the bone marrow sample, including peripheral blood blast percentage |
| Bone marrow blast percentage on bone marrow aspirate smear∗ |
| Presence of any significant (≥10%) dysplasia in each hematopoietic lineage (granulocytic, erythroid, and megakaryocytic) and any Auer rods |
| Presence or absence of ring sideroblasts on iron stain and their percentage of mature erythroid cells in the marrow |
| Bone marrow cellularity assessment (percentage) |
| Bone marrow fibrosis grade (MF 0-3) |
| Presence of any concomitant pathologies, such as metastasis, infection, lymphoma, mast cell disease, or multiple myeloma |
| Bone marrow karyotype (ISCN nomenclature) and any FISH results |
| Any pathogenic mutations identified on NGS panel, including VAF of each mutation |
ISCN, International System for Human Cytogenetic Nomenclature.
Blast estimation based on CD34 staining of the bone marrow biopsy should also be reported, if performed.